Enliven Therapeutics (NASDAQ:ELVN) Trading 4.7% Higher

Enliven Therapeutics, Inc. (NASDAQ:ELVN)’s share price traded up 4.7% on Thursday . The company traded as high as $18.12 and last traded at $18.12. 39,716 shares were traded during mid-day trading, a decline of 81% from the average session volume of 214,132 shares. The stock had previously closed at $17.30.

Wall Street Analyst Weigh In

Separately, Mizuho assumed coverage on shares of Enliven Therapeutics in a research report on Tuesday, April 9th. They issued a “buy” rating and a $34.00 target price for the company.

Enliven Therapeutics Price Performance

The business’s 50-day moving average is $17.05 and its two-hundred day moving average is $14.36.

Enliven Therapeutics (NASDAQ:ELVN) last released its earnings results on Thursday, March 14th. The company reported ($0.47) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.09. On average, equities analysts forecast that Enliven Therapeutics, Inc. will post -2.16 EPS for the current year.

Insider Activity

In other news, CEO Samuel Kintz sold 12,000 shares of Enliven Therapeutics stock in a transaction dated Thursday, January 25th. The shares were sold at an average price of $15.69, for a total value of $188,280.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Enliven Therapeutics news, Director Richard A. Heyman sold 1,270 shares of Enliven Therapeutics stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $19.99, for a total value of $25,387.30. Following the completion of the sale, the director now owns 137,155 shares in the company, valued at approximately $2,741,728.45. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Samuel Kintz sold 12,000 shares of the business’s stock in a transaction that occurred on Thursday, January 25th. The shares were sold at an average price of $15.69, for a total transaction of $188,280.00. The disclosure for this sale can be found here. Insiders sold a total of 763,661 shares of company stock valued at $13,213,762 in the last quarter. Company insiders own 45.80% of the company’s stock.

Institutional Investors Weigh In On Enliven Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in ELVN. Mirae Asset Global Investments Co. Ltd. grew its holdings in Enliven Therapeutics by 9.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,305 shares of the company’s stock worth $170,000 after acquiring an additional 1,029 shares during the last quarter. Deutsche Bank AG raised its holdings in Enliven Therapeutics by 16.7% during the third quarter. Deutsche Bank AG now owns 10,890 shares of the company’s stock worth $149,000 after buying an additional 1,559 shares during the last quarter. Legal & General Group Plc raised its holdings in Enliven Therapeutics by 8.9% during the third quarter. Legal & General Group Plc now owns 19,665 shares of the company’s stock worth $269,000 after buying an additional 1,610 shares during the last quarter. Tower Research Capital LLC TRC purchased a new stake in shares of Enliven Therapeutics in the first quarter valued at about $36,000. Finally, Charles Schwab Investment Management Inc. raised its holdings in shares of Enliven Therapeutics by 1.2% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 158,440 shares of the company’s stock valued at $2,193,000 after purchasing an additional 1,809 shares during the last quarter. 95.08% of the stock is owned by institutional investors.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.